PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634468
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634468
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is the name given to cancer that arises from plasmacytoid dendritic cells. Neoplasms that arise from immature cells that exhibit myeloid differentiation or from plasmacytoid dendritic cell progenitors are included in the 2016 WHO classification of "acute myeloid leukemia and associated neoplasms.". A total incidence of 0.04 cases of BPDCN were reported for every 100,000 people. The prognosis for BPDCN, a rare type of hematological cancer, is grim. Thanks to advancements in our understanding of the pathobiology of BPDCN and the emergence of novel immunotherapeutic strategies, patients with this aggressive neoplasm now have prospective treatment options.
Description
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a cancer that arises from plasmacytoid dendritic cells. Neoplasms that arise from immature cells that display myeloid differentiation or from plasmacytoid dendritic cell progenitors are included in the 2016 WHO classification of "acute myeloid leukemia and associated neoplasms.". Some of these conditions (myeloid sarcoma) include BPDCN, which is covered on this page, transitory aberrant myelopoiesis, myeloid leukemia linked to Down syndrome, and tumoral proliferation of myeloid blasts that devastate the underlying tissue architecture.
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) (Epidemiology)
A total incidence of 0.04 cases of BPDCN were reported for every 100,000 people. A bimodal distribution was present, with a higher incidence among those under 20 and over 60. Ladies had a significantly lower incidence than men did. The incidence of illness was 0.02/100000 in other races, significantly lower than it was in Caucasians. Over time, there was little change in the frequency of diseases.
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) -Current Market Size & Forecast Trends
The market for blastic plasmacytoid dendritic cell neoplasia (BPDCN) is projected to grow from approximately USD 136.72 million in 2024 to USD 282.81 million by 2034, reflecting a compound annual growth rate (CAGR) of 7.6% from 2025 to 2034. This growth is driven by the increasing incidence of BPDCN, advancements in diagnostic techniques, and the adoption of targeted therapies, particularly immunotherapies like tagraxofusp-erzs, which have shown promising results in clinical trials. North America currently holds the largest market share due to its advanced healthcare infrastructure and early adoption of innovative treatments, while Europe and the Asia Pacific regions are also experiencing steady growth supported by increasing awareness and improved healthcare systems. The ongoing development of precision medicine and collaborations between pharmaceutical companies and research institutions are expected to further enhance the market landscape as new therapeutic options emerge.
BPDCN is a rare type of hematological cancer with a poor prognosis. Thanks to advances in our understanding of the pathobiology of BPDCN and the emergence of novel immunotherapeutic strategies, patients with this aggressive neoplasm now have prospective therapeutic options. With the therapeutic approach for BPDCN becoming more standardized, a prognosis model for the best treatment risk stratification must be validated. Clarifying the molecular basis of BPDCN will make it easier to identify potential therapeutic targets for the condition. The market for Blast Plasmacytoid Dendritic Cell Neoplasia (BPDCN) will experience exponential growth, according to the analysis, because of issues with the currently approved medications that emerging medications like Pivekimab sunirine (ImmunoGen), Venetoclax (AbbVie/Genentech), and others can address. The length of the current therapies' remissions is uncertain, according to the Leukemia and Lymphoma Society (LLS).
Report Highlights
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - Current Market Trends
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - Current & Forecasted Cases across the G8 Countries
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - Market Opportunities and Sales Potential for Agents
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - Patient-based Market Forecast to 2035
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - Untapped Business Opportunities
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - Product Positioning Vis-a-vis Competitors' Products
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) - KOLs Insight
Table of Content
1. Blastic plasmacytoid dendritic cell neoplasia (BPDCN) Background
- 1.1. Blastic plasmacytoid dendritic cell neoplasia (BPDCN) Definition
- 1.2. Signs and Symptoms
- 1.3. Pathogenesis
- 1.4. Clinical Manifestation
- 1.5. Blastic plasmacytoid dendritic cell neoplasia (BPDCN) biomarkers
- 1.6. Diagnosis
2. Epidemiology Estimated and Forecast to 2035
- 2.1. Epidemiology Research Method & Data Sources Used
- 2.2. United States
- 2.2.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.2.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.3. United Kingdom
- 2.3.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.3.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.4. Spain
- 2.4.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.4.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.5. Germany
- 2.5.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.5.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.6. France
- 2.6.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.6.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.7. Italy
- 2.7.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.7.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.8. Japan
- 2.8.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.8.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.9. China
- 2.9.1. Incident Cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
- 2.9.2. Diagnosed and treatable cases of Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
- 2.10. Current Unmet Needs in Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by line of therapies (LOT)
3. Current Treatment Paradigm
- 3.1. Treatment/Prevention guidelines
- 3.2. Regulatory Approvals/Indication and Current Benchmarks
4. KOLs Insight (US, EU, JP, CH)
- 4.1. Unmet Needs
- 4.2. Analysis of the progress in terms of approvals & current pipeline
- 4.3. Impact on the treatment algorithm and product positioning
- 4.4. Relevance of new targets/platforms/ Therapy Uptake Share %
- 4.5. Physicians Preferences for the new pharmacological agents
5. What's New in 2024/2025
6. Future Treatment Paradigm
- 6.1. Blastic plasmacytoid dendritic cell neoplasia (BPDCN) Competitor Landscape and Approvals Anticipated
- 6.2. Future Treatment Algorithms and Competitor Positioning
- 6.3. Key Data Summary for Emerging Treatment
7. Late Phase Therapies Strategic Considerations in Blastic plasmacytoid dendritic cell neoplasia (BPDCN)
8. Total Market Forecast
- 8.1. Key Summary Findings
- 8.1.1. G8 total Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 8.1.2. G8 total Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
9. Market Forecast by Country
- 9.1. United States
- 9.1.1. United States Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.1.2. United States Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.2. Germany
- 9.2.1. Germany Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.2.2. Germany Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.3. France
- 9.3.1. France Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.3.2. France Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.4. Italy
- 9.4.1. Italy Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.4.2. Italy Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.5. Spain
- 9.5.1. Spain Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.5.2. Spain Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.6. United Kingdom
- 9.6.1. United Kingdom Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.6.2. United Kingdom Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.7. Japan
- 9.7.1. Japan Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.7.2. Japan Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
- 9.8. China
- 9.8.1. China Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) 2022-2035 (USD Million)
- 9.8.2. China Market for Blastic plasmacytoid dendritic cell neoplasia (BPDCN) by Therapies 2022-2035 (USD Million)
10. Market Drivers and Barriers
